June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Re-injections of Ranibizumab by first presence of intraretinal fluid do not improve the final BCVA when compared with re-injections given by recurrence of macular edema in patients with BRVO
Author Affiliations & Notes
  • Matus Rehak
    Department of Ophthalmology, University of Leipzig, Leipzig, Sachsen, Germany
  • Maria Tuisl
    Department of Ophthalmology, University of Leipzig, Leipzig, Sachsen, Germany
  • Annegret Franke
    Zentrum für klinische Studien, University of Leipzig, Leipzig, Sachsen, Germany
  • Peter MH Wiedemann
    Department of Ophthalmology, University of Leipzig, Leipzig, Sachsen, Germany
  • Footnotes
    Commercial Relationships   Matus Rehak, Alergan (R), Alimera (C), Bayer (C), Heidelberg (R), Novartis (F); Maria Tuisl, None; Annegret Franke, None; Peter Wiedemann, Bayer (R), Novartis (R)
  • Footnotes
    Support  Support for IIT by Novartis Pharma Germany
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1558. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Matus Rehak, Maria Tuisl, Annegret Franke, Peter MH Wiedemann; Re-injections of Ranibizumab by first presence of intraretinal fluid do not improve the final BCVA when compared with re-injections given by recurrence of macular edema in patients with BRVO. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1558.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate whether re-treatment with intravitreal application of ranibizumab given by the first observation of intraretinal fluid detected by optical coherence tomography (OCT) improves the final best corrected visual acuity (BCVA) at month 12 when compared with re-treatment given by presence of significant macular edema with decrease of BCVA

Methods : In total 18 treatment naive BRVO patients were included into the prospective interventional Trial ("Ranibizumab given by OCT") and randomized into two group. Both groups received 3 initial monthly ranibizumab injections. Furthre re-treatment was guided by OCT findings. The experimental group received re-applications by first presence of intraretinal fluid even the BCVA remained stable. In the control group the re-injections were given when the recurrence of macular edema with decrease of BCVA ≥5 ETDRS letters. Changes in BCVA in ETDRS letters, central retinal thickness (CRT), number of applied ranibizumab injections and rates of adverse events (AEs and SAEs) were documented over 12 months and compared between the study arms.

Results : TThe BCVA improved in experimental group at last visit (EoS=End of Study) compared to baseline in mean 4.3 (SD± 6.1) ETDRS letters and in the control group in mean 6.8 (SD± 10.6) ETDRS letters. The difference between both groups was not significant (-2,44 letters; (95%CI:-11.06;6.17) letters; p=0.556). Here, a rather smaller heterogeneity was observed with higher BCVA score within the experimental group. Only minor group difference was observed regarding the CRT between groups during the course of trial (the change at EoS visit compared to baseline was in the experimental arm CRT -42.2µm (SD± 76.9µm) compared to control group with -80.8µm (SD± 164.4µm). The patients in experimental group received in mean 9.2 (SD± 2.9) and the controls 6.8 (SD± 3.2) ranibizumab applications. No relevant AEs and SAEs were observed in both study arms during the entire trial.

Conclusions : The immediate re-injection by the first presence of intraretinal fluid did not significantly improve the finale functional results of ranibizumab treatment in patients with BRVO. A larger trial with longer follow-up is necessary to investigate the impact of intensified anti-VEGF treatment on macular morphology and long-time functional results.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×